Trump Administration Formally Nominates Dr. Heidi Overton as FDA Commissioner; PCAC Peptide Rulemaking Pipeline Now Runs Through Incoming Regime
President Trump announced Wednesday August 19, 2026 the formal nomination of Dr. Heidi Overton, a physician who currently works as deputy assistant to the president for domestic policy and formerly chief policy officer at America First Policy Institute, to serve as the next commissioner of the U.S. Food and Drug Administration. If confirmed by the U.S. Senate, Overton would take over from Kyle Diamantas (JD), who has served as acting commissioner since May 2026 following the departure of Marty Makary. Overton holds an MD from the University of New Mexico and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health, and served in the first Trump administration in the Office of American Innovation and Domestic Policy Council. She is Trump's third choice for the position after former Rep. Brad Wenstrup (R-Ohio) and acting Commissioner Diamantas both declined. The nomination matters for peptide-industry readers because the FDA rulemaking to translate the July 23-24 PCAC 6-peptide 503A recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) into a proposed rule (and eventually a final rule) will run through Overton's tenure if she is confirmed; the February 2027 PCAC meeting on cathelicidin, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF falls entirely within the window.